DALLAS, Texas–(BUSINESS WIRE)–Colossal Biosciences, the de-extinction company behind the woolly mammoth and thylacine, today announced the launch of Form Bio, a new independent company offering a breakthrough computational life sciences platform. Form Bio enters the market with an oversubscribed $30M Series A funding round led by JAZZ Venture Partners with participation from Thomas Tull, Colossal lead investor. Form Bio offers an advanced, comprehensive software platform that replaces cumbers
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.